Human Autologous Adipose Tissue
Shoulder Impingement Syndrome
Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Kessler Foundation
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03167138CT.gov Micro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Shoulder Impingement Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Autologous Adipose Tissue (this asset) | Kessler Foundation | Early P1 | C · 39 |
| Marcaine | Federal University of São Paulo | N/A | D |
| Autologous Conditioned Plasma | Ege University | N/A | D |
Other indications for Human Autologous Adipose Tissue
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Knee | — | P2 | CCC · 53 |
| Arthropathy | — | P2 | CCC · 53 |
| Rotator Cuff Syndrome | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Autologous Adipose Tissue in Shoulder Impingement Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-autologous-adipose-tissue-shoulder-impingement-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →